Core Viewpoint - The Commercial Health Insurance Innovative Drug Directory aims to provide a list of high-value innovative drugs that exceed basic medical insurance coverage, effective from January 1, 2026 [1][2]. Group 1: Overview of the Innovative Drug Directory - The directory includes 19 drugs focusing on three key areas: high-priced cancer treatments (5 Car-T cell therapy drugs), rare disease medications, and new targeted therapies for severe cancers [1]. - The directory is intended for reference by commercial health insurance and medical mutual aid systems, highlighting the importance of these drugs for patients with limited treatment options [1]. Group 2: Policy Implications - Drugs listed in the directory are not eligible for reimbursement under basic medical insurance, but the National Healthcare Security Administration has implemented a "three exclusions" policy to facilitate their use in hospitals [2]. - This policy alleviates concerns for hospitals regarding the use of innovative drugs, allowing for direct prescription and reimbursement through commercial insurance, thus bypassing previous complexities [2]. Group 3: Insurance Product Adaptation - Some commercial insurance products, such as certain惠民保 plans, have begun to incorporate drugs from the directory, offering increased reimbursement rates for hospital use of these drugs [2]. - Insurance companies are currently assessing how to integrate the directory's drugs into existing medical insurance products, with some already including specific innovative drugs as optional or mandatory coverage [3]. Group 4: Consumer Guidance - Consumers are advised to carefully review insurance contracts for coverage details, including specific drug lists, reimbursement rates, and any limitations on pharmacies or hospitals [4]. - Understanding the reimbursement process for innovative drugs is crucial, as it often involves specific purchasing locations, prescriptions from specialists, and prior authorization from insurance companies [4]. - Consumers should balance the cost of premiums with the level of coverage provided, considering personal health conditions and financial capabilities when deciding on insurance products that include innovative drug coverage [5].

没过几天，镇干部、施工方和我被请到一起开会，巡察组的同志就坐在我旁边。补偿款怎么算？补的地 选在哪儿？修水坝按啥标准？问题被一一摆上台面。最终方案清清楚楚：按今年邻地租金标准补偿我 350元；将村东头0.42亩机动地划拨给我；水坝结构按设计图纸复原，来年开春由镇里验收。白纸黑字 按上红手印，我这颗悬了几个月的心终于踏实了。 巡察组撤点前专门来回访。我领他们到地头，新修的挡水坝把水拢得妥妥帖帖，再也不用担心稻子抽穗 时缺水了。补偿款早已到账，补地协议也在村务公开栏里张贴公示。 守着田却种不了地，你说这心里是啥滋味？去年秋收刚过，村里修挡水坝，施工队一铲子下去，把我家 0.42亩口粮田并入了集体灌溉渠。地没了，稻茬还在地里撅着，看着实在揪心。 为这事儿我没少费心。找村干部，答复是"等镇上协调"；去镇里，他们摆手说"归水务局管"；问水务 局，得到的回复是"责任得现场认定"……这事儿像皮球一样被踢来踢去快一年，我的心也渐渐凉了。 转机出现在巡察组进驻之后。今年6月份，我听说市委巡察组进驻我们镇了，拿着土地承包证就找上了 门。"推诿扯皮伤民心，这个问题我们必须督促解决。"当天下午，他们就带着测量仪下了地，泥巴糊了 半裤 ...

Core Viewpoint - The announcement reveals that the controlling shareholder, Lao Bai Xi Medicine Group, has pledged 14 million shares of Lao Bai Xi Pharmacy, which raises concerns about the company's financial stability and stock performance [1] Share Pledge Situation - The total number of shares pledged by the controlling shareholder amounts to 114 million, representing 63.25% of their holdings and 15.04% of the company's total share capital [1][2] - The pledge is intended to meet the operational needs of the medicine group, which claims to have the ability to repay the funds, with repayment sources including dividends from the listed company and self-raised funds [2][3] Future Pledge and Reduction Plans - In the next six months, 12.35 million shares are set to mature, accounting for 6.84% of the controlling shareholder's holdings and 1.63% of the company's total shares, with a corresponding financing amount of 100 million [3] - The medicine group plans to reduce its holdings by 18.11 million shares between June 20 and July 30, 2025, at a price range of 17.60 to 21.55 yuan per share, totaling approximately 341 million [4] Financial Performance - Recent financial results show that the company experienced a revenue decline of 0.36% year-on-year in 2024, with a net profit drop of 44.13% [5] - For the first three quarters of 2025, both revenue and net profit continued to decline, with decreases of 1% and 16.11%, respectively [5] - The company's stock price has fallen over 70% from its peak of 53.14 yuan per share in 2020, closing at 15.26 yuan per share with a total market capitalization of 11.58 billion [5]

Group 1 - The controlling shareholder of the company, Lao Bai Xi Medicine Group Co., Ltd., holds approximately 180 million shares, accounting for 23.78% of the total share capital [1] - The total number of pledged shares by the controlling shareholder is about 114 million, representing 63.25% of the shares held and 15.04% of the total share capital [1] - The company’s revenue composition for the first half of 2025 indicates that retail pharmacy accounts for 81.81%, franchise and alliance distribution for 17.26%, and others for 0.93% [1] Group 2 - The company's market capitalization is currently 11.6 billion yuan [2]

证券代码：603883 证券简称：老百姓 公告编号：2025-072 被质押股份不存在被用作重大资产重组业绩补偿等事项的担保或其他保障用途情 老百姓大药房连锁股份有限公司 关于控股股东股票质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重要内容提示： ●老百姓大药房连锁股份有限公司（以下简称"公司"）控股股东老百姓医药集 团有限公司（以下简称"医药集团"）持有公司股份数量为 180,453,475 股，占公司 总股本比例为 23.78%；累计质押股份数量为 114,140,000 股（含本次质押），占其所 持股份比例为 63.25%，占公司总股本比例为 15.04%。控股股东及一致行动人（医药集 团与陈秀兰）合计持有公司股份数量为 194,019,173 股，占公司总股本比例为 25.57%； 累计质押股份数量为 114,140,000 股（含本次质押），占其所持股份比例为 58.83%， 占公司总股本比例为 15.04%。 一、上市公司股份质押 公司于 2025 年 12 月 24 日获悉控股股东医药集团所持有 ...

12月24日，国务院台办举行例行新闻发布会。有记者问：对于大陆方面揭批民进党当局打着"信任""繁 荣"的幌子滥施"金元外交"。台外事部门称，这是推动国际共荣发展的合作理念。请问发言人对此有何 评论？ 发言人彭庆恩表示，民进党当局口中所谓"以价值为本"，实质是"以'台独'为本"，为了谋"独"蓄意煽动 意识形态对立对抗；所谓"以人民福祉为核心"，实则是"以人民福祉为贡品"，挥霍台湾老百姓的血汗钱 换取所谓"国际空间"，卑鄙无耻。"台独"是走不通的绝路，无论民进党当局如何处心积虑搞小动作，都 改变不了台湾是中国一部分的事实，撼动不了国际社会坚持一个中国原则的格局。 ...

（编辑 王雪儿） 证券日报网讯 12月23日，老百姓发布公告称，截至本公告披露日，公司对外担保总额9.8亿元，占公司 最近一期经审计净资产的比例为13.69%，公司对外担保余额为4.4亿元（含本次担保），上述对外担保 总额全部为公司对合并报表范围内子公司提供的担保，公司不存在对控股股东和实际控制人及其关联人 提供担保情况，也不存在逾期对外担保情况。 ...

（一）担保的基本情况 证券代码：603883 证券简称：老百姓 公告编号：2025-071 关于为全资子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | 被担保人名称 | 本次担保金额 | 实际为其提供的 | 是否在前期预计 | 本次担保是否有 | | --- | --- | --- | --- | --- | | | | 担保余额（不含本 次担保金额） | 额度内 | 反担保 | | 丰沃达医药物流 （湖南）有限公司 | 18,000 万元 | 18,000 万元 | 是 | 否 | 累计担保情况 | 对外担保逾期的累计金额（万元） - | | | --- | --- | | 截至本公告日上市公司及其控股 | 98,000 | | 子公司对外担保总额（万元） | | | 对外担保总额占上市公司最近一 期经审计净资产的比例（%） | 13.69% | | 特别风险提示（如有请勾选） | □担保金额（含本次）超过上市公司最近一 期经审计净资产 50% □对外担保总额（ ...

Group 1 - The core event of the news is the completion of the "Old People's Traceability - Yunnan Baiyao" initiative, which aims to enhance public trust in the quality of traditional Chinese medicine through a transparent supply chain [1] - A strategic cooperation signing ceremony was held between Yunnan Baiyao and Lao Baixing Pharmacy in Kunming, focusing on creating a new blueprint for the pharmaceutical health industry [1] - The traceability initiative involved a thorough verification of the ecological planting environment and standardized management processes in the core production area of Sanqi in Wenshan [1] Group 2 - The traceability event utilized a Douyin micro-variety live broadcast format, attracting over 100,000 viewers and effectively communicating the value of traceability [1] - Yunnan Baiyao employs a proprietary seed bank to cultivate high-activity seedlings, ensuring the quality of traditional medicine from the source [2] - The partnership aims to expand from Sanqi to other traditional Chinese medicine categories, focusing on high-quality development and innovative pharmaceutical services [2]

Core Viewpoint - The recent appreciation of the Renminbi (RMB) is seen as beneficial for domestic consumption and reducing import costs, but there are concerns about calls for a significant appreciation that could harm the economy [1][3][21] Group 1: Economic Impact of RMB Appreciation - The moderate appreciation of the RMB aligns well with the domestic strategy to expand internal demand, leading to lower import costs and increased disposable income for consumers [3][21] - China, as the world's largest crude oil importer, has seen a 3.2% year-on-year increase in crude oil imports, totaling 521.87 million tons in the first eleven months [3] - The reduction in import costs for crude oil and other commodities, such as synthetic fiber and soybeans, alleviates financial pressure on households, allowing for increased spending in sectors like tourism, education, and health [3][4] Group 2: Risks of Significant RMB Appreciation - Experts advocating for a drastic appreciation of the RMB by 50% may overlook the potential negative consequences, such as the risk of economic instability similar to Japan's experience post-Plaza Accord [4][20] - A rapid appreciation could severely impact export-oriented businesses, which typically operate on thin profit margins of 3% to 5%, potentially leading to cash flow issues and the elimination of many small and medium enterprises [17][21] - The argument for significant appreciation based on purchasing power parity is criticized for ignoring the differences in economic structures and cost compositions between countries [12][14][16]